Eckert & Ziegler stock faces earnings test after Ac-225 approval
Published on 11/05/2026 at 10:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSRegulatory progress meets earnings test
- GMP authorization supports clinical supply of Actinium-225 and planned capacity expansion.
- NuWays expects adjusted EBIT growth in the third quarter, driven by isotope products, Lu-177 revenue and licensing income.
- Eckert & Ziegler is scheduled to publish its quarterly figures on November 12.
Eckert & Ziegler stock traded at 14.18 euros on Lang & Schwarz at 10:33 CET on Thursday, November 5, 2026, 1.29 percent above the Xetra close of Wednesday, November 4. The share is now heading toward a quarterly report that will show whether the expected recovery in operating performance is taking shape.
The regulatory backdrop was strengthened on October 28, when Eckert & Ziegler Therapeutics GmbH received authorization to manufacture Actinium-225 under Good Manufacturing Practice standards. The wholly owned subsidiary can use the certified process for material intended for investigational patient treatments. The company is also preparing further capacity steps, including a commercial-scale facility in China targeted for initial operations in early 2027.
Production milestone and financial outlook
Börse Express reported that NuWays kept its buy rating and a 21.50-euro price target unchanged in an analysis dated October 19. The broker expects adjusted EBIT to return to growth in the third quarter. The cited drivers are a recovery in the Isotope Products business, higher revenue from Lutetium-177 and licensing income.
That forecast addresses a different question from the Actinium-225 authorization. GMP approval establishes a production basis for clinical and future commercial programs, but it does not itself provide a reported earnings contribution or guarantee drug approvals. The upcoming figures therefore offer the next financial test for the investment case.
Eckert & Ziegler's quarterly results are scheduled for November 12. Investors will be watching for evidence of the expected operating recovery, progress in isotope products and any indication of how the new Actinium-225 platform could develop into customer supply.
For a direct market view, use the real-time quote of Eckert & Ziegler stock.
Eckert & Ziegler stock at a glance
- Company: Eckert & Ziegler SE
- ISIN: DE0005659700
- WKN: 565970
- Ticker: EUZ.DE
- Exchange: Xetra
- Lang & Schwarz quote: 14.18 euros, Thursday, November 5, 2026, 10:33 CET
- Change versus Xetra close: +1.29 percent versus 14.00 euros on Wednesday, November 4, 2026
The DAX provides the relevant German market backdrop.
More news and analyses on Eckert & Ziegler stock will follow the November 12 results and the next capacity milestones.
